Literature DB >> 16563355

High-affinity binding of the NC1 domain of collagen VII to laminin 5 and collagen IV.

Raymond Brittingham1, Jouni Uitto, Andrzej Fertala.   

Abstract

Anchoring functions of collagen VII depend on its ability to form homotypic fibrils and to bind to other macromolecules to form heterotypic complexes. Biosensor-based binding assays were employed to analyze the kinetics of the NC1 domain-mediated binding of collagen VII to laminin 5, collagen IV, and collagen I. We showed that collagen VII interacts with laminin 5 and collagen IV with a Kd value of 10(-9) M. In contrast, the NC1-mediated binding to collagen I was weak with a Kd value of 10(-6) M. Binding assays also showed that the NC1 domain utilizes the same region to bind to both laminin 5 and collagen IV. We postulate that the ability of the NC1 domains to bind with high affinities to laminin 5 and collagen IV facilitates stabilization of the structure of the basement membrane itself and that the NC1-collagen I interaction may be less important for stabilization of the dermal-epidermal junction.

Mesh:

Substances:

Year:  2006        PMID: 16563355     DOI: 10.1016/j.bbrc.2006.03.034

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  24 in total

1.  The epidermal basement membrane is a composite of separate laminin- or collagen IV-containing networks connected by aggregated perlecan, but not by nidogens.

Authors:  Daniel Timo Behrens; Daniela Villone; Manuel Koch; Georg Brunner; Lydia Sorokin; Horst Robenek; Leena Bruckner-Tuderman; Peter Bruckner; Uwe Hansen
Journal:  J Biol Chem       Date:  2012-04-09       Impact factor: 5.157

2.  Epidermolysis bullosa. II. Type VII collagen mutations and phenotype-genotype correlations in the dystrophic subtypes.

Authors:  Roslyn Varki; Sara Sadowski; Jouni Uitto; Ellen Pfendner
Journal:  J Med Genet       Date:  2006-09-13       Impact factor: 6.318

3.  Protein therapeutics for junctional epidermolysis bullosa: incorporation of recombinant beta3 chain into laminin 332 in beta3-/- keratinocytes in vitro.

Authors:  Olga Igoucheva; Aislinn Kelly; Jouni Uitto; Vitali Alexeev
Journal:  J Invest Dermatol       Date:  2007-12-13       Impact factor: 8.551

4.  The cysteine-rich region of type VII collagen is a cystine knot with a new topology.

Authors:  Henrik Wegener; Hauke Paulsen; Karsten Seeger
Journal:  J Biol Chem       Date:  2014-01-02       Impact factor: 5.157

5.  Supramolecular interactions in the dermo-epidermal junction zone: anchoring fibril-collagen VII tightly binds to banded collagen fibrils.

Authors:  Daniela Villone; Anja Fritsch; Manuel Koch; Leena Bruckner-Tuderman; Uwe Hansen; Peter Bruckner
Journal:  J Biol Chem       Date:  2008-07-03       Impact factor: 5.157

Review 6.  Minor collagens of the skin with not so minor functions.

Authors:  Georgios Theocharidis; John T Connelly
Journal:  J Anat       Date:  2017-02-02       Impact factor: 2.610

7.  Engineering and characterization of the chimeric antibody that targets the C-terminal telopeptide of the α2 chain of human collagen I: a next step in the quest to reduce localized fibrosis.

Authors:  Jolanta Fertala; Andrzej Steplewski; James Kostas; Pedro Beredjiklian; Gerard Williams; William Arnold; Joseph Abboud; Anshul Bhardwaj; Cheryl Hou; Andrzej Fertala
Journal:  Connect Tissue Res       Date:  2013-04-15       Impact factor: 3.417

Review 8.  Type VII collagen: the anchoring fibril protein at fault in dystrophic epidermolysis bullosa.

Authors:  Hye Jin Chung; Jouni Uitto
Journal:  Dermatol Clin       Date:  2010-01       Impact factor: 3.478

9.  Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression.

Authors:  Manisha Tripathi; Srinivas Nandana; Hironobu Yamashita; Rajkumar Ganesan; Daniel Kirchhofer; Vito Quaranta
Journal:  J Biol Chem       Date:  2008-09-09       Impact factor: 5.157

Review 10.  Developmental and pathogenic mechanisms of basement membrane assembly.

Authors:  Peter D Yurchenco; Bruce L Patton
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.